Switzerland The CEO of Siemens’ Healthineers Switzerland explains the reasons behind the spinoff of the former Siemens AG segment and elaborates how the Healthineers are positioning themselves to become the main driver of global medical technology trends. In 2015, Siemens made its healthcare segment an independent organization and most recently changed…
Switzerland The general manager of ResMed’s Swiss affiliate explains the company’s efforts to raise the awareness of sleep apnea in the country, and elaborates on how Switzerland can act as a “role model” for the other affiliates of the Group. As much as 80 percent of all sleep apnea cases worldwide…
Switzerland Nasri Nahas, CEO of Biopôle in Switzerland, discusses his motivations for joining the biotech, and his mission to re-position the organization as a life sciences ecosystem bringing together academia, business, and research. What motivated you to join Biopôle in October 2015? I began my career as a molecular biologist in France…
Switzerland The Chairman of Ferring’s Group Operating Committee and Senior Vice President Europe-Canada elaborates on how Europe can be the thinking engine for global pharmaceutical trends. Ferring has bundled the European and Canadian markets into one single region. Could you please introduce us to the full scope of your role…
Switzerland An expert in the implementation of Swiss federal laws within Switzerland’s constituent cantons, Giovan Maria Zanini discusses the evolution of Swiss pharma regulatory framework and efforts to strengthen and protect the country’s world leading innovation environment. Dr. Zanini, you have been described as “the expert in the cantonal implementation of…
Switzerland Switzerland may have a world class healthcare system, but small adjustments are needed to ensure incentives for payer and providers are properly aligned with the patient’s ultimate quality and value of care. Dr. Cassis, could you please introduce yourself, with reference to your experience and current responsibilities in the realm…
Switzerland Advances in delivery technology and manufacturing costs have driven a surge of activity in peptide drug development, says Thomas Früh, CEO of Bachem – the largest and most advanced peptide drug CMO in the world. Peptide therapeutics are a hot topic in the pharma industry today – what’s the story…
Switzerland Outsourcing of API synthesis has stabilized in the decade since Rohner Chem entered the pharma sector in earnest, and according to CEO Daniel Pedrett the company has reached a position where it is faster, more agile and more experienced than the internal supply organizations of many mid-sized innovators. You were…
Switzerland Helsinn is a leader in cancer supportive care, and Vice Chairman and CEO Riccardo Braglia enthusiastically discusses the Group’s entrance into the field of oncology therapeutics and the launch of the new Helsinn Investment Fund. Helsinn Advanced Synthesis in Biasca is a very advanced site capable of synthesizing high…
Switzerland With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market Manager Giampiero Roncoroni discusses the unique features of the Swiss market, and how a particular focus on the OTC/OTX market has been a key factor of success…
Switzerland With 40 years of history in Switzerland, B Braun serves every hospital in the country and operates three distinct production sites. CEO Madeleine Stöckli discusses her strategy for improving productivity and finding opportunities for growth. Could you please briefly introduce yourself and B Braun Switzerland to our readers? B Braun…
Switzerland Sintetica, Switzlerland’s longtime leader in local anesthesia and pain relief with development efforts in neuromodulation, started an ambitious internationalization strategy in 2011. CEO Augusto Mitidieri discusses the company’s expansion progress and highlights areas of unmet medical need around anesthetics. What are the most significant unmet medical needs in the realm…
See our Cookie Privacy Policy Here